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commentaries
ing from a clinical standpoint. It is reminiscent of the oft-noted clinical findings
in hypertrophic cardiomyopathy wherein
the degree of diastolic impairment is
often described as “out of proportion”
to the observed ventricular hypertrophy,
thus suggesting a significant myocellular
contribution to disease pathogenesis. It
is interesting to speculate that the wellknown salutary effects of postinfarction
treatment with metoprolol may reflect the
molecular findings in the current paper.
Thus the results presented by Perrino et al.
lay the groundwork for a robust 2-pronged
therapeutic approach based on relief of the
inciting pathogenic stimulus and direct
treatment of the underlying molecular
derangements, perhaps via novel compounds to displace active PI3K isoforms
from the receptor complex.
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Mechanisms of sympathoadrenal failure
and hypoglycemia in diabetes
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A reduced sympathoadrenal response, induced by recent antecedent hypoglycemia, is the key feature of hypoglycemia-associated autonomic failure
(HAAF) and, thus, the pathogenesis of iatrogenic hypoglycemia in diabetes.
Understanding of the mechanism(s) of that reduced response awaits new
insight into its basic molecular, cellular, organ, and whole-body physiology and pathophysiology in experimental models. In this issue of the JCI,
McCrimmon and colleagues report that application of urocortin I (a corticotrophin-releasing factor receptor–2 agonist) to the ventromedial hypothalamus reduces the glucose counterregulatory response to hypoglycemia
in rats (see the related article beginning on page 1723). Thus, hypothalamic
urocortin I release during antecedent hypoglycemia is, among other possibilities, a potential mechanism of HAAF.
Nonstandard abbreviations used: HAAF, hypoglycemia-associated autonomic failure; T1DM, type 1 diabetes mellitus; VMH, ventromedial hypothalamus.
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The clinical problem of iatrogenic hypoglycemia in people with diabetes mellitus (1)
has stimulated bidirectional translational
research. That included, initially, patientoriented research based on the then-existing body of knowledge and, more recently,
basic research into the molecular, cellular,
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organ, and whole-body physiology of glucose counterregulation — the mechanisms
that normally prevent or rapidly correct
hypoglycemia — and its pathophysiology
in experimental models (2). The latter is
exemplified by the report from McCrimmon and colleagues (3) in this issue of the
JCI. In the aggregate, such basic research
will undoubtedly lead to more informative studies in humans and, hopefully, the
ultimate elimination of hypoglycemia from
the lives of people with diabetes.
The clinical problem is clear to millions
of people with diabetes and, increasingly,
to their caregivers: iatrogenic hypoglycemia
is the limiting factor in the glycemic management of diabetes (1, 2). It causes recurrent morbidity in most people with type 1
diabetes mellitus (T1DM) and many with
T2DM and is sometimes fatal. The barrier
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Figure 1
Physiological and behavioral defenses against hypoglycemia. Decrements in insulin and increments in glucagon are lost and increments in epinephrine and neurogenic symptoms are often attenuated in insulin-deficient — T1DM and advanced T2DM — diabetes. SNS, sympathetic nervous system; PNS, parasympathetic nervous system; NE, norepinephrine; ACh, acetylcholine; α cell, pancreatic islet α cells; β cell, pancreatic islet β cells.

of hypoglycemia precludes maintenance
of euglycemia over a lifetime of diabetes
and, thus, full realization of the now wellestablished vascular benefits of glycemic
control (4, 5). Even asymptomatic episodes
of hypoglycemia impair defenses against
subsequent hypoglycemia by causing hypoglycemia-associated autonomic, specifically sympathoadrenal, failure and thus a
vicious cycle of recurrent hypoglycemia.
Compromised defenses
against hypoglycemia
The physiological defenses against falling
plasma glucose concentrations (Figure 1)
include: (a) decreased pancreatic islet β cell
insulin secretion; (b) increased pancreatic
islet α cell glucagon secretion; and, absent
the latter, (c) increased adrenomedullary epi-

nephrine secretion (6). The behavioral form
of defense (Figure 1) is the ingestion of food
prompted by symptoms of hypoglycemia
(6). All of these defenses are compromised
(1, 2) in T1DM (7) and advanced T2DM (8).
This involves both peripheral (pancreatic
islet) and CNS alterations. Both decrements
in insulin and increments in glucagon are
lost. The former is the result of β cell failure.
The latter is plausibly attributed to loss of
the decrement in intra-islet insulin that normally signals increased glucagon secretion
(9–11). In the setting of absent insulin and
glucagon responses, attenuated epinephrine responses cause the clinical syndrome
of defective glucose counterregulation
that is associated with a 25-fold or greater
increased risk of severe hypoglycemia (1, 2).
Attenuated sympathoadrenal, largely sym-
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pathetic neural (12), responses also cause
the clinical syndrome of hypoglycemia
unawareness that, by compromising the
behavioral defense, is also associated with
an increased risk of severe hypoglycemia (1,
2). Thus, hypoglycemia is the result of the
interplay of absolute or relative (to exogenous glucose delivery, endogenous glucose
production, or insulin sensitivity) therapeutic insulin excess and compromised glucose
counterregulation (1, 2, 13).
Hypoglycemia-associated
autonomic failure
The concept of hypoglycemia-associated
autonomic failure (HAAF) in T1DM (7) and
advanced T2DM (8) (Figure 2) posits that
recent antecedent iatrogenic hypoglycemia
causes both defective glucose counterregu-
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Figure 2
HAAF in T1DM and advanced T2DM. Figure modified from the New England Journal of Medicine, with permission from the Massachusetts Medical Society (1).

lation and hypoglycemia unawareness and,
thus, a vicious cycle of recurrent hypoglycemia (1, 2). It causes defective glucose
counterregulation by reducing epinephrine
responses to a given level of subsequent
hypoglycemia in the setting of absent decrements in insulin and increments in glucagon. It causes hypoglycemia unawareness by reducing sympathoadrenal and the
resulting neurogenic symptom responses
to a given level of subsequent hypoglycemia. Sleep and antecedent exercise cause
a similar phenomenon (1) (Figure 2). The
clinical impact of HAAF, including the
finding that hypoglycemia unawareness
and the reduced epinephrine component
of defective glucose counterregulation are
reversed by as little as 2–3 weeks of scrupulous avoidance of hypoglycemia in most
affected patients, is well established (1, 2).
However, the mechanism(s) of the key feature of HAAF, the attenuated sympathoadrenal response to falling plasma glucose
concentrations, are unknown (2).
The shift of the glycemic thresholds
for sympathoadrenal responses to lower
plasma glucose concentrations caused by
recent antecedent hypoglycemia (or by
sleep or prior exercise) could be the result
of alterations in the peripheral afferent or
efferent components of the autonomic nervous system or within the CNS (2). Much
of the recent research has focused on the
latter, especially the hypothalamus (2, 3).
However, hypoglycemia activates wide1472

spread brain regions including the medial
prefrontal cortex (14).
The potential CNS mechanisms of the
reduced sympathoadrenal response, and
thus of HAAF, have been reviewed (2). In my
view (2), the balance of evidence, including
more recent evidence (15), weighs heavily
against the systemic mediator (e.g., cortisol)
hypothesis and the brain fuel (e.g., glucose)
transport hypothesis, although increased
transport of other fuels remains to be
explored fully (16). Thus, assuming a primary CNS alteration, the global brain metabolism hypothesis is the most attractive. The
array of potential mechanisms within the
brain (reviewed in ref. 2) range from posthypoglycemic increased glucokinase activity in critical hypothalamic neurons (17)
to posthypoglycemic brain glycogen supercompensation (18). In addition, alterations
of ATP-sensitive K+ channel function, AMPactivated protein kinase activity, γ-amino
butyric acid release, insulin signaling, and
expression of angiotensinogen and related
genes as well as of paraventricular nucleus
activity, cerebral glucose metabolism, and
cerebral blood flow have been proposed
(2). The findings of McCrimmon and colleagues (3) raise another possibility. They
report that ventromedial hypothalamus
(VMH) application of urocortin I, a corticotrophin-releasing factor receptor–2 agonist,
suppresses the counterregulatory response
to hypoglycemia (an effect that lasted for
at least 24 hours), whereas that of cortico-
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trophin-releasing factor, a predominant
corticotrophin-releasing factor receptor–1
agonist, amplifies that response in rats. Urocortin I was also shown to alter the glucose
sensitivity of VMH glucose-sensing neurons
in whole-cell current clamp experiments in
brain slices. Thus, increased hypothalamic
urocortin I release during antecedent hypoglycemia could explain a decreased sympathoadrenal response to subsequent hypoglycemia. However, that causal connection was
not demonstrated and, therefore, remains a
provocative theoretical possibility.
Ultimately, the problem of hypoglycemia
(and that of hyperglycemia) in diabetes will
likely be solved by the development of safe
and effective methods that provide plasma
glucose–regulated insulin replacement
or secretion. That will probably involve
closed-loop insulin replacement (online
glucose sensor–computer interface–insulin infusion pump) until implantation
of glucose-responsive, insulin-secreting
cells becomes feasible for widespread use.
Pending that, there is clear a need for new
insight into the fundamental mechanisms
of the physiology of glucose counterregulation and its pathophysiology in experimental models that leads to clinical strategies
that are then shown to both reduce the risk
of hypoglycemia and facilitate glycemic
control in people with diabetes (i.e., bidirectional translational research).
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Genetic defects in the transcription factor forkhead box protein P3 (Foxp3)
cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked
(IPEX). IPEX is thought to be due to a defect in naturally arising CD4+ Tregs.
In this issue of the JCI, Bacchetta and colleagues demonstrate that patients
with IPEX and missense mutations in Foxp3 provide insight into the role of
various domains of Foxp3 in the development and function of Tregs (see the
related article beginning on page 1713).
In the past decade, naturally arising
CD4+CD25+ Tregs have emerged as being
critical for the maintenance of peripheral
immunological tolerance (1). Neonatal
thymectomy in mice and thymic hypoplasia in humans (DiGeorge syndrome)
result in impaired Treg generation and
in the development of organ-specific
autoimmune diseases (2, 3). Treg generation in the thymus requires interaction
with MHC class II molecules expressed by
cortical epithelial cells (4). Other signals
have also been implicated, including those
delivered by CD28, CD40 ligand, and the
cytokines TNF-α and TGF-β (5). However,
IL-2, which is necessary for Treg survival
Nonstandard abbreviations used: FKH, forkhead;
Foxp3, forkhead box protein P3; GITR, glucocorticoidinduced TNF receptor; IPEX, immune dysregulation,
polyendocrinopathy, enteropathy, X-linked.
Conflict of interest: The authors have declared that no
conflict of interest exists.
Citation for this article: J. Clin. Invest. 116:1473–1475
(2006). doi:10.1172/JCI28880.

in the periphery, is dispensable for their
development (6, 7).
Tregs represent a small subset of CD4+ T
cells (5–10%). They express several surface
markers including CD25 (the IL-2 receptor
α-chain), CTL-associated antigen 4 (CTLA4),
and glucocorticoid-induced TNF receptor (GITR). However, these molecules are
upregulated in naive CD4+CD25– T cells following TCR stimulation and cannot therefore serve as absolute Treg markers. Recently,
several groups identified the forkhead family transcription factor forkhead box protein
P3 (Foxp3) as a specific molecular marker
of Tregs (8, 9). Foxp3 expression seems
to be largely restricted to a small subset of
TCRαβ T cells and defines 2 pools of Tregs
with suppressive activity: CD4+CD25high cells
and a minor population of CD4+CD25low/–
T cells. Thus, Foxp3 expression correlates
better with suppressor activity than CD25
expression (10). Ectopic expression of Foxp3
in vitro and in vivo is sufficient to convert
naive murine CD4+ T cells to Tregs (11).
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In contrast, overexpression of FOXP3 in
human CD4+CD25– T cells in vitro is not
sufficient to generate potent suppressor
activity, suggesting that additional factors
are required for bona fide Treg activity (12).
Foxp3 expression cannot be readily induced
in murine T cells by stimulation in vitro. In
humans, cross-linking of the TCR and CD28
stimulation, or antigen-specific stimulation, can induce CD4+CD25– Foxp3– cells
to become Tregs and express FOXP3 and
exert suppressor function (11, 13). These
results suggest that de novo generation of
Tregs may be a natural consequence of the
immune response in humans.
Tregs are anergic in vitro. They fail to proliferate and secrete IL-2 in response to TCR
ligation, and they depend on IL-2 generated
following activation of CD4+CD25– T cells to
survive and exert their function. An in vitro
assay that measures the ability of CD4+CD25+
T cells to suppress CD4+CD25– T cell proliferation is commonly used to assess Treg
function (14). The mechanisms mediating
the suppression of immune responses in
vivo by Tregs are still unclear. Several studies
support the involvement of contact-dependent inhibition, while others suggest that
Tregs can exert their function by secreting
immunosuppressive cytokines such as IL-10
or TGF-β or by directly killing their target in
a perforin-dependent manner (15).
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